Analyst consensus rating
Aldeyra Therapeutics Analyst Rating: Strong Buy
ALDX is rated Strong Buy by 5 analysts with a $6.60 target. As of 2026-08-30.
Direct answer
Aldeyra Therapeutics's consensus rating is Strong Buy.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $6.60.
Forecast evidence checked August 30, 2026.
Get free Aldeyra Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.49
- Average price target
- $6.60
- High price target
- $13.00
- Low price target
- $2.00
- Low target gap
- +34.7%
- Target upside
- +344.4%
- High target gap
- +775.4%
- Target range width
- 740.7%
- Consensus rating
- Strong Buy
- Analysts
- 5
- Evidence date
- August 30, 2026
- Valid through
- September 6, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Aldeyra Therapeutics?
Aldeyra Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $6.60.
How far are Aldeyra Therapeutics's low and high targets from the recorded price?
The low target implies +34.7%, while the high target implies +775.4%.
How many analysts are included in Aldeyra Therapeutics's consensus?
The verified consensus includes 5 analysts.
How is Aldeyra Therapeutics's target upside or downside calculated?
The average target of $6.60 is divided by the recorded price of $1.49, then one is subtracted to produce +344.4%. This does not guarantee a future return.
When was Aldeyra Therapeutics's analyst forecast verified?
The data was verified on 2026-08-30. The dataset is valid through 2026-09-06.